— Renowned founder and robotics visionary joins AiM at a pivotal growth inflection point —
WORCESTER, Mass., March 11, 2026 (GLOBE NEWSWIRE) — AiM Medical Robotics Inc. (AiM), a company developing next-generation MRI-compatible robotic systems for neurosurgery and beyond, today announced the appointment of surgical-robotics pioneer Yulun Wang, PhD, to its Board of Directors. The appointment further complements and strengthens AiM’s strategic leadership and governance as the company advances from first-in-human studies toward regulatory clearance and commercial launch of its stereotactic neurosurgery robot, which is focused on the 10 billion dollar addressable market of neurostimulation electrode placement for Parkinson’s disease, depression, tremors, as well as tumor ablations and other critical health-improving procedures.
Dr. Yulun Wang is one of the most accomplished innovators and entrepreneurs in surgical robotics and digital health. The founder of surgical robotics pioneer Computer Motion, Dr. Wang was the principal architect and inventor of AESOP, the first FDA-approved surgical robot, and the ZEUS robotic surgical system, which performed the world’s first remote surgery, the TransAtlantic Lindbergh Operation, in 2001. He currently serves as Co-Founder and Executive Chairman of Sovato Health, which is focused on enabling remote surgery and procedures at commercial scale. He has founded multiple category-defining companies, including Computer Motion, which was acquired by Intuitive Surgical, Inc., and InTouch Health, a pioneer in telemedicine, which was acquired by Teladoc Health. Over more than four decades, Dr. Wang has consistently transformed breakthrough engineering concepts into scalable, clinically adopted platforms, delivering exceptional strategic and investor value across the healthcare technology landscape.
“AiM is addressing a clear unmet need at the intersection of neurosurgery, robotics, and advanced imaging,” said Dr. Wang. “The company’s MRI-compatible robotic architecture is both technically differentiated and commercially compelling. I see strong alignment between AiM’s technology, its disciplined development strategy, and the requirements for long-term value creation. I’m excited to support the team as they move toward clinical and commercial milestones.”
AiM’s Chief Executive Officer and Founder, Dr. Gregory Fischer, commented: “Yulun’s decision to join our Board is a powerful external validation of AiM’s technology, strategy, and execution. He brings unmatched experience in building robotic platforms from concept through regulatory approval, market adoption, and strategic exit. His guidance will be instrumental as we transition from advanced development into clinical deployment and commercial release.”
Chief Medical Officer Dr. Jonathan Sackier added: “From an investor and clinical perspective, AiM is relentlessly focused on executing the right priorities in the right sequence. Dr. Wang’s experience bridges engineering excellence, clinical realism, and capital efficiency. His insight will strengthen our clinical and business strategy and help ensure that our technology delivers measurable value to patients, providers, and healthcare systems. Having worked with him at Computer Motion and InTouch, I am personally familiar with his wisdom, drive, and refuse-to-lose attitude.”
Dr. Wang’s appointment comes as AiM Medical Robotics advances its MRI-guided robotic platform designed to improve precision, reproducibility, and workflow efficiency in stereotactic and functional neurosurgical procedures. The company’s strategy emphasizes capital-efficient development, clear regulatory pathways, and alignment with established clinical reimbursement frameworks.
About AiM Medical Robotics
AiM Medical Robotics is a privately held medical device company based in Worcester, MA, developing next-generation MRI-compatible robotic systems to enable highly precise and efficient image-guided neurosurgical interventions. AiM’s compact and portable robotic surgery platform integrates actuated instrument alignment into existing clinical workflows while enabling continuous, real-time visualization during surgery. By integrating robotics directly within the MRI environment, AiM aims to reduce procedural variability, improve safety, reduce procedure time, and expand access to advanced neurosurgical care. The company is focused on scalable platform development with clear regulatory and commercial pathways. Looking ahead, AiM plans to harness the power of artificial intelligence to enhance its robotic platform, creating an intelligent surgical ecosystem that can learn from real-world data, optimize workflows, and provide surgeons with predictive insights in real time. By combining advanced intelligent robotics with intraoperative imaging, AiM seeks to unlock a new era of accessible, faster, safer, and more precise brain surgery.
To learn more about AiM Medical Robotics and its neurosurgical robotics platform, visit https://www.aimmedicalrobotics.com/ and follow the company on LinkedIn at http://www.linkedin.com/company/aim-medical-robotics.
Forward-Looking Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are based on AiM’s current expectations, estimates, and projections about our industry, our business, and the device we are developing, and are subject to substantial risks, uncertainties, and assumptions. The statements concern AiM’s business strategies; research and development plans; the timing of regulatory submissions; the ability to obtain and maintain regulatory authorizations of AiM’s products; market acceptance of AiM’s products; AiM’s intellectual property; AiM’s reliance on third-party organizations; AiM’s competitive position; AiM’s industry environment; AiM’s anticipated financial and operating results, including anticipated sources of revenue; AiM’s assumptions regarding the size of the available market and the benefits of AiM’s products; product pricing and timing of product launches; management’s expectations with respect to future acquisitions; AiM’s goals, intentions, plans, and expectations, including the introduction of new products and markets; and AiM’s cash needs and financing plans.
Actual events may differ materially from the expectations indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which can be identified by words such as “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “will,” “continue,” “predict,” “potential,” “project,” or similar terms, variations of such terms, or the negative of those terms. AiM’s medical device is currently in development and remains subject to significant risks and uncertainties, including, but not limited to, delays or difficulties in preclinical and clinical testing, obtaining required regulatory authorizations, supply chain and manufacturing challenges, changes in market conditions, and potential competition. The timing and outcome of regulatory reviews and clinical trial results are inherently uncertain and could adversely affect the commercial viability of AiM’s products. AiM may not realize its expectations or achieve its plans, and actual results may differ materially from those indicated by these forward-looking statements as a result of various factors. All forward-looking statements reflect the current beliefs and assumptions of AiM management as of the date of this press release and should be regarded solely as AiM’s current plans, estimates, and beliefs. AiM cannot guarantee future results, events, or performance. AiM does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances, or the occurrence of unanticipated events, except as may be required by applicable law.
Media Contact:
John Gomes
Chief Commercial Officer
[email protected]
617-203-5565
Investors:
Investor Relations
[email protected]
- AiM Medical Robotics Inc.
- AiM Medical Robotics Inc.